Shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) have been given a consensus rating of “Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $12.00.
A number of research firms recently issued reports on ARCT. Zacks Investment Research cut Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 19th. Brookline Capital Management reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a report on Thursday, September 27th. ValuEngine cut Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Finally, WBB Securities raised Arcturus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 20th.
Shares of NASDAQ ARCT traded down $0.01 during midday trading on Monday, reaching $4.68. 11,044 shares of the company traded hands, compared to its average volume of 20,524. The stock has a market cap of $48.67 million, a PE ratio of -1.33 and a beta of 1.93. Arcturus Therapeutics has a 12 month low of $4.11 and a 12 month high of $10.45.
Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.04. The company had revenue of $3.42 million for the quarter, compared to the consensus estimate of $3.75 million. Equities analysts forecast that Arcturus Therapeutics will post -1.9 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Worth Venture Partners LLC acquired a new stake in shares of Arcturus Therapeutics during the third quarter worth $290,000. ARK Investment Management LLC raised its holdings in shares of Arcturus Therapeutics by 45.0% during the third quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock worth $6,840,000 after purchasing an additional 239,999 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Arcturus Therapeutics by 91.7% during the third quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 8,008 shares during the period. Finally, BlackRock Inc. acquired a new stake in shares of Arcturus Therapeutics during the second quarter worth $169,000. 10.09% of the stock is owned by institutional investors and hedge funds.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Featured Story: What Factors Can Affect Return on Equity?